The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A prospective study of XELIRI plus bevacizumab as the first-line therapy in Japanese patients with unresectable or recurrent colorectal cancer (KSCC1101).
 
Koichi Hanazono
No Relationships to Disclose
 
Yasunori Emi
No Relationships to Disclose
 
Akihito Tsuji
No Relationships to Disclose
 
Fumiaki Kishihara
No Relationships to Disclose
 
Eiji Oki
No Relationships to Disclose
 
Masahiro Hamanoue
No Relationships to Disclose
 
Hideo Baba
No Relationships to Disclose
 
Shoji Natsugoe
No Relationships to Disclose
 
Yutaka Ogata
No Relationships to Disclose
 
Kenji Sakai
No Relationships to Disclose
 
Yoshihiko Maehara
No Relationships to Disclose